Novogen Leaps on News of Successful Anti-Cancer Stem Cell Breakthrough

Michael Teague  |

The Australian drug manufacturer Novogen Limited (NVGN) saw its shares skyrocket as much as 260 percent to $7.52 by mid-Tuesday, upon the release of news that trials for their experimental anti-cancer drug CS-6 have proven conclusively successful.

According to a company press-release yesterday “The study was designed to test the ability of the experimental anti-cancer drug, CS-6, to kill ovarian cancer stem cells.”  Cancer stem-cells, while thought to make up only a small fraction (less than 1 percent) of all cells active in leukemia as well as gut, skin, ovarian, and brain cancers, are thought by scientists to be the reason that such cancers are able to return, usually in a more virulent, untreatable form, after the preliminary success of radio and chemotherapy treatments.

In December of last year, Novogen completed its acquisition of Triaxial Pharmaceuticals, which provided it with the technology necessary to develop the CS-6 drug that has the capacity to target not only human cancer cells but also stem-cells.  According to the press release, “CS-6 belongs to a new class of drug candidates known (structurally) as super-benzopyrans displaying potent anti-cancer activity and demonstrating increased bio-availability to cancer cells”.

The study was conducted by Mazor Oncology, an affiliate of Yale University that specializes in cancer stem-cell research as well as in testing the viability of experimental anti-cancer drugs.  While CS-6 was originally developed to treat giloma, a form of brain cancer, it has already proven effective against ovarian cancer and researchers are predicting that the technology should be applicable to a range of other types of cancer in which cancer stem-cells play a major role.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Array
(
    [0] => 
    [1] => 
    [2] => 
    [3] => 
    [4] => 
    [5] => 
)

	

Companies

Symbol Name Price Change % Volume
NVGN KZIA Novogen Limited n/a n/a n/a n/a

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
GOOG

     
XOM

     
BRK.A

     
FB

     
JNJ

     
WFC

     
T

     
NFLX

     
TSLA

     
V

     
UNH

     
PG

     

World Economic Forum at Davos 2019 - Ben Yablon Executive VP Salt Lending

Matt Bird sits down with Ben Yablon - Executive VP of Salt Lending - at the World Economic Forum in Davos January 2019